Recent results from the TETON-1 phase 3 clinical trial assessing inhaled treprostinil to treat idiopathic pulmonary fibrosis ...

Clinically meaningful HRQOL gains persisted to week 52 with mean changes of −1.66 (HEIS), −8.5 (DLQI), and +0.20 (EQ-5D-5L), ...

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 ...

Outcome-weighted metrics (mortality, 5-year survival, MIR) better capture unmet need than incidence alone when assessing ...

New findings from the SPIRIT-HF (NCT04727073) trial are helping to refine the clinical role of spironolactone (Aldactone; ...

Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient ...

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending. In this Q&A, Urick discusses the ...

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 ...

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and ...

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives ...

Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...

CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...